URINARY INCONTINENCE TREATMENT DRUGS MARKET ANALYSIS

Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023
Code : CMI4400
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key players are manufacturing urinary incontinence treatment drugs with advanced treatment methods in emerging economies, and this isexpected to boost demand for urinary incontinence treatment drugs market in the Middle East region. For instance, in December 2022, according to an article published by PubMed Central, a study was conducted in the United Arab Emirates which showed that the quality of life was impaired in an estimated 90% of patients with urinary incontinence. Therefore, the increasing burden of urinary incontinence among women and the aging population increases demand for urinary incontinence treatment drugs.

Global Urinary Incontinence Treatment Drugs Market - Key Players

Major players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG, elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH.